SQI has continued its positive momentum over the last year, signing five service agreements with drug development companies. The company also broadened its commercial focus in 2014 with a deal to automate DNA-based pathogen detection assays, a new application for its technology. We now look towards the conversion of customers from early contract work/validation to full commercialisation. Despite the encouraging deal progress, we reduce our valuation to C$55m vs C$60m previously (C$0.98 per share vs C$1.07), mainly due to the more protracted time frame for the phasing of contracts to reach significant revenue recognition.

SQI Diagnostics is a Canadian diagnostics company. It develops and sells multiplexed research diagnostics to pharmaceutical companies to support clinical research, and in vitro diagnostics tests to centralised diagnostics labs for diagnosing autoimmune diseases.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports

Merrill Lynch (NYSE:SQD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Merrill Lynch.
Merrill Lynch (NYSE:SQD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Merrill Lynch.